ACR20 response

Group by Anti-TNFα	Study name	Statistics for each study: Risk ratio	Lower limit	Upper limit	Events / Total: Anti-TNFα	Control
Adalimumab	van de Putte et al, 2004 (30)	2.41	1.56	3.72	52 / 113	21 / 110
Adalimumab		2.41	1.56	3.72		
Etanercept	Moreland et al, 1999 (24)	5.24	2.76	9.97	46 / 78	9 / 80
Etanercept		5.24	2.76	9.97		
Overall		3.42	1.60	7.30		

Risk ratio and 95% CI

ACR50 response

Group by Anti-TNF	Study name	Statistics for each study: Risk ratio	Lower limit	Upper limit	Events / Total: Anti-TNFα	Control
Adalimumab	van de Putte et al, 2004 (30)	2.704	1.322	5.529	25 / 113	9 / 110
Adalimumab		2.704	1.322	5.529		
Etanercept	Moreland et al, 1999 (24)	7.949	2.943	21.467	31 / 78	4 / 80
Etanercept		7.949	2.943	21.467		
Overall		4.378	1.531	12.518		

Risk ratio and 95% CI



ACR70 response

Group by Anti-TNF	Study name	Statistics for each study: Risk ratio	Lower limit	Upper limit	Events / Total: Anti-TNFα	Control
Adalimumab	van de Putte et al, 2004 (30)	6.81	1.59	29.29	14 / 113	2 / 110
Adalimumab		6.81	1.59	29.29		
Etanercept	Moreland et al, 1999 (24)	11.28	1.49	85.32	11 / 78	1 / 80
Etanercept		11.28	1.49	85.32		
Overall		8.10	2.48	26.43		

Risk ratio and 95% CI